• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

    88.44 +1.85 (+2.14%)
    Streaming Delayed Price Updated: 11:54 AM EST, Feb 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Protagonist Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    News headline image
    Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026
    Via ACCESS Newswire
    News headline image
    Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance ↗
    This clinical-stage biotech focused on peptide therapeutics reported significant insider selling amid a year of strong stock performance. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes ↗
    The chief medical officer at one of the top pharmaceutical companies sold nearly 10,000 shares in late January 2026, but the reason was for something very simple. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    "Animal Spirits" Return: Morgan Stanley Signals M&A Renaissance as Healthcare and Industrials Lead Shifting Landscape
    As 2026 begins, the global mergers and acquisitions (M&A) market is witnessing a profound "renaissance," driven by a confluence of stabilizing interest rates, record levels of corporate cash, and a... 
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    BMO Capital Lifts Protagonist Therapeutics Target On J&J Deal Hopes — Retail Traders Pile In ↗
    Via Stocktwits
    News headline image
    Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
    Via ACCESS Newswire
    News headline image
    Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    News headline image
    Protagonist (PTGX) Earnings Call Transcript ↗
    Protagonist (PTGX) Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice
    Via ACCESS Newswire
    News headline image
    Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    Via ACCESS Newswire
    News headline image
    Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting
    Via ACCESS Newswire
    News headline image
    What 7 Analyst Ratings Have To Say About Protagonist Therapeutics ↗
     
    Via Benzinga
    News headline image
    Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences
    Via ACCESS Newswire
    News headline image
    Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 Million ↗
    Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 Million 
    Via The Motley Fool
    Topics Energy
    News headline image
    Moody Aldrich Fully Exits 136K SKWD Shares Worth $7.8 Million ↗
    Moody Aldrich Fully Exits 136K SKWD Shares Worth $7.8 Million 
    Via The Motley Fool
    News headline image
    Moody Aldrich Liquidates Entire Stake in PLMR Worth $8.2 Million ↗
    Moody Aldrich Liquidates Entire Stake in PLMR Worth $8.2 Million 
    Via The Motley Fool
    Topics Regulatory Compliance
    Big Pharma Just Put Peptides Back on the Map – Which Players Are Still Under the Radar?
    Via AB Newswire
    News headline image
    2 Top Dividend Kings Every Income Investor Should Own ↗
    These companies pay durable and steadily rising dividends. 
    Via The Motley Fool
    Topics Bonds
    News headline image
    Johnson & Johnson's M&A Strategy Is the Real Story for Investors ↗
    Johnson & Johnson’s rumored Protagonist buyout demonstrates its proven M&A strategy: divesting low-growth units to fund high-margin, innovative assets. 
    Via MarketBeat
    News headline image
    Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook ↗
    Johnson & Johnson beats Q3 estimates, raises 2025 sales guidance, and announces plans to spin off its $9.2 billion orthopedics business, DePuy Synthes. 
    Via Benzinga
    News headline image
    Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print ↗
    Investors may also look for updates on J&J’s reported talks to acquire Protagonist Therapeutics to bolster its immunology and oncology pipeline. 
    Via Stocktwits
    Topics Government World Trade
    News headline image
    Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch ↗
    Johnson & Johnson stock trades near all-time highs with an upcoming Q3 earnings report acting as the next catalyst. 
    Via Benzinga
    News headline image
    FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy ↗
    FDA updates Johnson & Johnson's Carvykti label to warn of rare immune-related enterocolitis while reaffirming the therapy's overall benefit. 
    Via Benzinga
    News headline image
    Wall Street Suffers Worst Day Since April as Trump Revives Trade War Fears ↗
    U.S. markets were rattled on Friday after President Trump reignited trade tensions with China, triggering the sharpest sell-off since April. Tech and AI stocks led the decline, while gold and... 
    Via Chartmill
    Topics Artificial Intelligence Government World Trade
    News headline image
    Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today ↗
    The company could soon be swallowed by a very large peer -- which also happens to be a business partner. 
    Via The Motley Fool
    News headline image
    Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
    Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. 
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Friday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report ↗
    Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that could expand its immunology and cancer drug portfolio. 
    Via Benzinga
    News headline image
    Which stocks are experiencing notable movement on Friday? ↗
    Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session. 
    Via Chartmill
    News headline image
    5 Analysts Assess Protagonist Therapeutics: What You Need To Know ↗
     
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.